The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1Areceptor antagonist
Open accessAbstract
Background and purpose: Cannabis is the source of at least seventy phytocannabinoids. The pharmacology of most of these has been little investigated, three notable exceptions being Δ 9‐tetrahydrocannabinol, cannabidiol and Δ 9‐tetrahydrocannabivarin. This investigation addressed the question of whether the little‐studied phytocannabinoid, cannabigerol, can activate or block any G protein‐coupled receptor. Experimental approach: The [35 S]GTPγS binding assay, performed with mouse brain membranes, was used to test the ability of cannabigerol to produce G protein‐coupled receptor activation or blockade. Its ability to displace [3 H]CP55940 from mouse CB 1 and human CB 2 cannabinoid receptors and to inhibit electrically evoked contractions of the mouse isolated vas deferens was also investigated. Key results: In the brain membrane experiments, cannabigerol behaved as a potent α 2‐adrenoceptor agonist (EC 50= 0.2 nM) and antagonized the 5‐HT 1A receptor agonist,R‐(+)‐8‐hydroxy‐2‐(di‐n‐propylamino)tetralin (apparent KB= 51.9 nM). At 10 µM, it also behaved as a CB 1 receptor competitive antagonist. Additionally, cannabigerol inhibited evoked contractions of the vas deferens in a manner that appeared to be α 2‐adrenoceptor‐mediated (EC 50= 72.8 nM) and displayed significant affinity for mouse CB 1 and human CB 2 receptors. Conclusions and implications: This investigation has provided the first evidence that cannabigerol can activate α 2‐adrenoceptors, bind to cannabinoid CB 1 and CB 2 receptors and block CB 1 and 5‐HT 1A receptors. It will now be important to investigate why cannabigerol produced signs of agonism more potently in the [35 S]GTPγS binding assay than in the vas deferens and also whether it can inhibit noradrenaline uptake in this isolated tissue and in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Chemical constituents of marijuana: The complex mixture of natural cannabinoids
ElSohly, M. A., & Slade, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.011 · Cited by 1,094
Ross, R. A., Gibson, T. M., Brockie, H. C., Leslie, M., Pashmi, G., Craib, S. J., Di Marzo, V., & Pertwee, R. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703850 · Cited by 237 · cited 2×
“…the CB1-selective antagonist, rimonabant, when this was administered at 100 nM, a concentration higher than that required to antagonize the established cannabinoid receptor agonists, CP55940, R-(+)-WIN55212 and D9-tetrahydrocannabinol, in the same bioassay (Pertwee et al., 1995; Ross et al., 2001).”
Background
Cited by
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationTaming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Phytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Bonini, S. A., Premoli, M., Tambaro, S., Kumar, A., Maccarinelli, G., Memo, M., & Mastinu, A. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.09.004 · Cited by 669
Metadata
- Authors
- Cascio, M., Gauson, L., Stevenson, L., Ross, R., & Pertwee, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 159
- Issue
- 1
- Pages
- 129-141
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1898835919
- Cited by
- 241
- References
- 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1Areceptor antagonist. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00515.x
- The paper
- Cascio, M., Gauson, L., Stevenson, L., Ross, R., & Pertwee, R. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1Areceptor antagonist. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00515.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.